A new clinical trial by Northwestern University and University of Florida found that nicotinamide riboside, a form of vitamin B3, improved walking distance in patients with peripheral artery disease. Over six months, those taking nicotinamide riboside walked 17 meters further than those on placebo, highlighting its potential for enhancing endurance in PAD, a condition with limited treatments.
Nicotinamide riboside boosts NAD+ levels, crucial for energy production and reducing oxidative stress in muscles. The study, published in Nature Communications, involved 90 participants aged around 71, showing promising results in improving walking performance among PAD patients.
Researchers also explored nicotinamide riboside’s synergy with resveratrol but found no added benefits. The compound has gained popularity for its anti-aging properties, contributing over $60 million in sales. Future studies will further assess its benefits in broader populations.
